Work

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.9520

Authors: Harry J.M. Groen, Wallace L. Akerley, Pierre Jean Souquet, Eckart Laack, Ji-Youn Han, Egbert F. Smit, Aaron Scott Mansfield, Edward B. Garon, Juergen Wolf, Daniel Shao-Weng Tan, Rebecca Suk Heist, Maeve Waldron-Lynch, Sylvie Le Mouhaer, Ngozi Nwana, Monica Giovannini, Sergey Orlov

Institutions: University Medical Center Groningen, University of Groningen, Huntsman Cancer Institute, Hôpital Lyon Sud, National Cancer Center, The Netherlands Cancer Institute, Mayo Clinic, University of California, Los Angeles, University Hospital Cologne, National Cancer Centre Singapore, Massachusetts General Hospital, Novartis (Switzerland), Novartis (France), Novartis (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3030375299

Cites:

Cited by: 10

Related to: 10